首页> 外文期刊>Journal of viral hepatitis. >Fibrosis progression in initially mild chronic hepatitis C.
【24h】

Fibrosis progression in initially mild chronic hepatitis C.

机译:最初轻度慢性丙型肝炎的纤维化进展。

获取原文
获取原文并翻译 | 示例
           

摘要

The natural history of chronic hepatitis C presenting with no/minimal liver fibrosis is uncertain with controversies on risk of progression and need for antiviral treatment. We studied rates and determinants of fibrosis progression in initially mild chronic hepatitis C. One hundred and six patients (mean age 41.65 +/- 12.83 years) with chronic hepatitis C virus infection and no/minimal fibrosis in the initial liver biopsy (F0/F1 by METAVIR score) were followed prospectively while untreated with repeated biopsy after 5 or more years (mean interval 7.8 +/- 1.51 years). Patients showing fibrosis progression were compared with nonprogressors for baseline and follow-up parameters. Sixty-four patients (60.4%) showed fibrosis progression including 13 of 27 (49%) with F0 and 51 of 79 (65%) with F1. Progression to F3 or cirrhosis was seen in 36% of those with F1 initially. Fibrosis progression (DeltaF/year) was associated with age (P < 0.0001), baseline and follow-up alanine aminotransferase (ALT) (P = 0.005), histological activity (P = 0.004) and steatosis (P = 0.002) in the initial biopsy and use of alcohol (P = 0.008). Thus liver fibrosis progression occurs in two-thirds of patients with initially mild chronic hepatitis C within 5-10 years and advanced fibrosis/cirrhosis develops in one-third of those with F1 initially. Fibrosis is facilitated by older age and alcohol and associated with inflammatory activity and ALT levels. Antiviral therapy should be considered in mild chronic hepatitis C.
机译:慢性丙型肝炎无/无肝纤维化的自然病史尚不确定,存在进展风险和需要抗病毒治疗的争议。我们研究了最初轻度慢性丙型肝炎的纤维化进展速度和决定因素。最初肝活检(F0 / F1)中有106例(平均年龄41.65 +/- 12.83岁)慢性丙型肝炎病毒感染且无/最小纤维化的患者随访5年或5年以上(平均间隔7.8 +/- 1.51年),未经治疗则进行前瞻性随访。将显示纤维化进展的患者与未进展的患者进行基线和随访参数比较。六十四名患者(60.4%)显示出纤维化进展,其中27名中的13名(49%)为F0,而51名中的51名(65%)为F1。最初有F1的患者中有36%会进展为F3或肝硬化。最初的纤维化进展(DeltaF /年)与年龄(P <0.0001),基线和后续丙氨酸氨基转移酶(ALT)(P = 0.005),组织学活性(P = 0.004)和脂肪变性(P = 0.002)相关。活检和酒精使用(P = 0.008)。因此,在5-10年内,三分之二的患有轻度慢性丙型肝炎的患者发生肝纤维化的进展,而最初为F1的患者中有三分之一的患者发生了晚期纤维化/肝硬化。老年人和酒精会促进纤维化,并与炎症活动和ALT水平相关。轻度慢性丙型肝炎应考虑抗病毒治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号